Verve Therapeutics Stock Buy Hold or Sell Recommendation
| VERV Stock | USD 6.58 0.30 4.36% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Verve Therapeutics is 'Strong Sell'. Macroaxis provides Verve Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VERV positions. The advice algorithm takes into account all of Verve Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Verve Therapeutics' buy or sell advice are summarized below:
Real Value 6.6 | Target Price 44.22 | Hype Value 6.88 | Market Value 6.58 | Naive Value 6.89 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Verve Therapeutics given historical horizon and risk tolerance towards Verve Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Verve Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Verve |
Execute Verve Therapeutics Buy or Sell Advice
The Verve recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Verve Therapeutics. Macroaxis does not own or have any residual interests in Verve Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Verve Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Verve Therapeutics Trading Alerts and Improvement Suggestions
| Verve Therapeutics generated a negative expected return over the last 90 days | |
| Verve Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (149.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 87.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from accesswire.com: INVESTOR ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm |
Verve Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Verve analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Verve analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Verve Therapeutics Returns Distribution Density
The distribution of Verve Therapeutics' historical returns is an attempt to chart the uncertainty of Verve Therapeutics' future price movements. The chart of the probability distribution of Verve Therapeutics daily returns describes the distribution of returns around its average expected value. We use Verve Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Verve Therapeutics returns is essential to provide solid investment advice for Verve Therapeutics.
| Mean Return | -0.61 | Value At Risk | -6.17 | Potential Upside | 7.36 | Standard Deviation | 6.37 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Verve Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Verve Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verve Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verve Therapeutics backward and forwards among themselves. Verve Therapeutics' institutional investor refers to the entity that pools money to purchase Verve Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2023-12-31 | 2.1 M | Arch Venture Corp | 2023-12-31 | 2 M | Novo A/s | 2023-12-31 | 2 M | Baker Bros Advisors Lp | 2023-12-31 | 1.7 M | Ecor1 Capital, Llc | 2023-12-31 | 1.2 M | Geode Capital Management, Llc | 2023-12-31 | 1.1 M | Goldman Sachs Group Inc | 2023-12-31 | 947.2 K | Redmile Group, Llc | 2023-09-30 | 809.8 K | Bvf Inc | 2023-09-30 | 650 K | Alphabet Inc | 2023-12-31 | 12.3 M | Ark Investment Management Llc | 2023-12-31 | 7 M |
Verve Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Verve Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Verve Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Verve stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.97 | |
β | Beta against NYSE Composite | 4.17 | |
σ | Overall volatility | 6.46 | |
Ir | Information ratio | -0.11 |
Verve Therapeutics Volatility Alert
Verve Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Verve Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Verve Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Verve Therapeutics Fundamentals Vs Peers
Comparing Verve Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Verve Therapeutics' direct or indirect competition across all of the common fundamentals between Verve Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Verve Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Verve Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Verve Therapeutics to competition |
| Fundamentals | Verve Therapeutics | Peer Average |
| Return On Equity | -0.35 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (10.49) % | (5.51) % |
| Current Valuation | 26.26 M | 16.62 B |
| Shares Outstanding | 83.62 M | 571.82 M |
| Shares Owned By Insiders | 7.64 % | 10.09 % |
| Shares Owned By Institutions | 87.15 % | 39.21 % |
| Number Of Shares Shorted | 15.36 M | 4.71 M |
| Price To Earning | 5.45 X | 28.72 X |
| Price To Book | 1.06 X | 9.51 X |
| Price To Sales | 54.05 X | 11.42 X |
| Revenue | 11.76 M | 9.43 B |
| Gross Profit | (128.15 M) | 27.38 B |
| EBITDA | (217.67 M) | 3.9 B |
| Net Income | (200.07 M) | 570.98 M |
| Cash And Equivalents | 293.56 M | 2.7 B |
| Cash Per Share | 4.90 X | 5.01 X |
| Total Debt | 74.91 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 11.55 X | 2.16 X |
| Book Value Per Share | 7.31 X | 1.93 K |
| Cash Flow From Operations | (149.55 M) | 971.22 M |
| Short Ratio | 12.95 X | 4.00 X |
| Earnings Per Share | (3.12) X | 3.12 X |
| Target Price | 32.13 | |
| Number Of Employees | 255 | 18.84 K |
| Beta | 1.7 | -0.15 |
| Market Capitalization | 575.3 M | 19.03 B |
| Total Asset | 752.69 M | 29.47 B |
| Retained Earnings | (544.3 M) | 9.33 B |
| Working Capital | 600.94 M | 1.48 B |
| Net Asset | 752.69 M |
Note: Acquisition by Kathiresan Sekar of 526000 shares of Verve Therapeutics subject to Rule 16b-3 [view details]
Verve Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Verve . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Verve Therapeutics Buy or Sell Advice
When is the right time to buy or sell Verve Therapeutics? Buying financial instruments such as Verve Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 2.0M | 81.9M | 74.9M | 70.2M | Total Assets | 384.1M | 679.2M | 752.7M | 421.5M |
Use Investing Ideas to Build Portfolios
In addition to having Verve Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Automobiles and Trucks Thematic Idea Now
Automobiles and Trucks
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Automobiles and Trucks theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Automobiles and Trucks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Verve Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Verve Stock analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Verve Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.183 | Quarterly Revenue Growth 4.083 | Return On Assets (0.19) | Return On Equity (0.35) |
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.